Literature DB >> 14639659

TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.

Xabier Agirre1, Francisco J Novo, María J Calasanz, María J Larráyoz, Idoya Lahortiga, Mikel Valgañón, Marina García-Delgado, José L Vizmanos.   

Abstract

Different mechanisms, such as chromosomal rearrangements, deletions, mutations, and methylation/demethylation of the promoter regions of genes, have been shown to be involved in acute lymphoblastic leukaemia (ALL). These genetic and epigenetic alterations lead to the activation of protooncogenes or to inactivation of tumour suppressor genes promoting cell proliferation. One of the most frequently inactivated tumour suppressor genes is TP53, which is altered in 50% of human tumours. In this study, we have analysed: (1) the complete coding region, all intron-exon junctions and noncoding regions of exons 1-11 of TP53 by lexon-DGGE; (2) the methylation status of the 5' region of TP53 and (3) the deletion of one or both alleles of the gene by fluorescence in situ hybridisation (FISH) in 57 ALL patients. Using these techniques, we have found promoter methylation in 32% of the cases, missense mutations in 8.8%, and deletion of one allele in 7.5% of the samples, with TP53 being altered in 40% of the ALL samples studied in this series. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639659     DOI: 10.1002/mc.10159

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

1.  RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines.

Authors:  Feng-Xian Zhai; Xiang-Fu Liu; Rui-Fang Fan; Zi-Jie Long; Zhi-Gang Fang; Ying Lu; Yong-Jiang Zheng; Dong-Jun Lin
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-18       Impact factor: 4.553

Review 2.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 3.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Structure and activity of putative intronic miRNA promoters.

Authors:  Alex Mas Monteys; Ryan M Spengler; Ji Wan; Luis Tecedor; Kimberly A Lennox; Yi Xing; Beverly L Davidson
Journal:  RNA       Date:  2010-01-14       Impact factor: 4.942

5.  Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.

Authors:  Hajime Isomoto; Justin L Mott; Shogo Kobayashi; Nathan W Werneburg; Steve F Bronk; Serge Haan; Gregory J Gores
Journal:  Gastroenterology       Date:  2006-11-07       Impact factor: 22.682

6.  Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.

Authors:  Elena N Voropaeva; Tatyana I Pospelova; Mikhail I Voevoda; Vladimir N Maksimov; Yuriy L Orlov; Olga B Seregina
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

7.  VentX trans-activates p53 and p16ink4a to regulate cellular senescence.

Authors:  Xiaoming Wu; Hong Gao; Weixiong Ke; Martin Hager; Sheng Xiao; Michael R Freeman; Zhenglun Zhu
Journal:  J Biol Chem       Date:  2011-02-16       Impact factor: 5.157

8.  p53 null fluorescent yellow direct repeat (FYDR) mice have normal levels of homologous recombination.

Authors:  Dominika M Wiktor-Brown; Michelle R Sukup-Jackson; Saja A Fakhraldeen; Carrie A Hendricks; Bevin P Engelward
Journal:  DNA Repair (Amst)       Date:  2011-10-12

9.  Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro.

Authors:  Xiao Zhang; Andrew D Wallace; Pan Du; Simon Lin; Andrea A Baccarelli; Hongmei Jiang; Nadereh Jafari; Yinan Zheng; Hehuang Xie; Marcelo Bento Soares; Warren A Kibbe; Lifang Hou
Journal:  Environ Toxicol Pharmacol       Date:  2012-08-01       Impact factor: 4.860

10.  Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.

Authors:  Walid Sabri Hamadou; Sawsen Besbes; Violaine Bourdon; Yosra Ben Youssef; Mohamed Adnène Laatiri; Testsuro Noguchi; Abderrahim Khélif; Hagay Sobol; Zohra Soua
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.